Danish Novo Nordisk is moving out of the diabetes space and taking over Prothenas ATTR amyloidosis programme – including a Phase II-ready immunotherapy.
This white paper explores the drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2021-07-06 11:45:002021-07-06 11:45:00Azafaros appoints Stefano Portolano as CEO
With a €20m financing round under its belt, Promethera Therapeutics is poised to start its Phase IIb study for its stem cell therapy treating liver failure.
Early-stage venture capital investor Novalis Biotech has closed its Biotech Acceleration Fund at €25m to drive growth of translational medicine start-ups.
The Thermo Scientific HyPerforma GXCore Bioprocess Controller is an innovative, compact, cost-effective, open-architecture controller built for research and process development applications.
Novo Nordisk invests in amyloidosis pipeline
Latest NewsDanish Novo Nordisk is moving out of the diabetes space and taking over Prothenas ATTR amyloidosis programme – including a Phase II-ready immunotherapy.
Sanofi invests heavily in multiple myeloma pipeline
Latest NewsSanofi is shelling out US$1bn for a license granting the French pharma company access to a potential multiple myeloma treatment.
Bio-Me raises NOK10m
Latest NewsOslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
Drug repurposing trends shorten timelines
Sponsored PublicationsThis white paper explores the drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
Azafaros appoints Stefano Portolano as CEO
AppointmentsDr Stefano Portolano, M.D., is the new Chief Executive Officer of Azafaros and has been appointed to the Board of Directors of the Dutch company.
NFL Biosciences goes public, raises €5m
Latest NewsFrench biopharma company NFL Biosciences has raised €5m following its IPO at Euronext Growth Paris.
Promethera bags €20m for liver failure treatment
Latest NewsWith a €20m financing round under its belt, Promethera Therapeutics is poised to start its Phase IIb study for its stem cell therapy treating liver failure.
Novalis Biotech closes biotech fund at €25m
Latest NewsEarly-stage venture capital investor Novalis Biotech has closed its Biotech Acceleration Fund at €25m to drive growth of translational medicine start-ups.
Cellink AB to take-over Discover Echo Inc
Latest NewsSwedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.
Thermo Scientific HyPerforma GXCore Bioprocess Controller
ProductsThe Thermo Scientific HyPerforma GXCore Bioprocess Controller is an innovative, compact, cost-effective, open-architecture controller built for research and process development applications.